LVGO Livongo Health

Livongo Expands Relationship with CVS Health, Now Part of Chronic Condition Management Platform within Point Solutions Service

Livongo Expands Relationship with CVS Health, Now Part of Chronic Condition Management Platform within Point Solutions Service

CVS Health pharmacy benefit management clients can now easily implement the Livongo for Diabetes, Hypertension, Weight Management, and Diabetes Prevention programs through an alternative contracting path

MOUNTAIN VIEW, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- Livongo (Nasdaq: LVGO), the leading Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, today announced that it is available through the CVS Health Point Solutions Management service. Point Solutions Management is a full service offering for CVS Caremark pharmacy benefit management (PBM) clients to contract, onboard, and manage health and care solutions including Livongo’s Diabetes, Hypertension, Weight Management, and Diabetes Prevention programs. 

Livongo and CVS Health have collaborated since 2017 through CVS Health’s Transform Diabetes Care Program, which includes the Livongo for Diabetes, Livongo for Hypertension, and Livongo for Diabetes Prevention programs. With the Point Solutions Management service, CVS Health clients not currently using Livongo can now add Livongo’s proven solutions through an alternative contracting path.

“Together Livongo and CVS Health are focused on creating the best possible Member and client experience and one that leads to measurable clinical outcomes and financial returns,” said Livongo President Dr. Jennifer Schneider, M.D., M.S. “Through an additional contracting path, we can effectively reach more Members, providing them a better overall chronic condition management experience. This is another significant step in furthering our mission of empowering people with chronic conditions to live better and healthier lives.”

Through its AI+AI engine, Livongo uses its connected ecosystem to collect data, which includes cellular-connected devices and integration with continuous glucose monitors, and then applies advanced data science to create detailed Member profiles that includes personal health and medication trends.

As of March 2, 2020, Livongo has more than 800 clients, including more than 30 percent of Fortune 500 companies, four of the top seven health plans, health systems, government organizations, and labor unions. Through a combination of advanced technology, data science, and personalized coaching, Livongo creates a world class Member experience that delivers sustained results for people living with multiple chronic conditions. A  presented at the American Heart Association’s 2019 Scientific Sessions showed that people with both diabetes and elevated blood pressure who used Livongo’s integrated platform saw sustained clinically-significant blood pressure reduction after only four weeks and experienced further improvements after using the program for twelve weeks.

About Livongo

Livongo empowers people with chronic conditions to live better and healthier lives, beginning with diabetes and now including hypertension, weight management, diabetes prevention, and behavioral health.  Livongo pioneered the category of Applied Health Signals to offer Members clinically-based insights that focus on the whole person and make it easier to stay healthy.  Using its AI+AI engine, Livongo’s team of data scientists aggregate and interpret substantial amounts of health data and information to create actionable, personalized and timely health signals delivered to Livongo Members exactly when and where they need them.  The Livongo approach delivers better clinical and financial outcomes while creating a different and better experience for people with chronic conditions. For more information, visit: or engage with Livongo on or .

Livongo Media Contact:

Jake Mazanke



630-640-5253

Livongo Investor Contact:

John Hallock



617-615-7712

EN
12/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Livongo Health

 PRESS RELEASE

Livongo Reports Third Quarter 2020 Financial Results

Livongo Reports Third Quarter 2020 Financial Results Third quarter total revenue of $106.1 million, up 126% year-over-yearOver 442,000 enrolled Livongo for Diabetes Members, up 113% year-over-year MOUNTAIN VIEW, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Livongo Health, Inc. (NASDAQ: LVGO), the leading Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, today announced financial results for its third quarter ended September 30, 2020. “Livongo delivered another quarter of greater than 100% revenue growth, driven by stronger than...

 PRESS RELEASE

Livongo to Release Results for the Third Quarter of Fiscal Year 2020

Livongo to Release Results for the Third Quarter of Fiscal Year 2020 MOUNTAIN VIEW, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Livongo Health, Inc., (Nasdaq: LVGO) today announced it will release its financial results for its third quarter of fiscal year 2020 on October 28, 2020, after close of the U.S. stock market. Given the pending transaction with Teladoc Health, Livongo is not hosting a conference call in conjunction with its third quarter of 2020 earnings release. About Livongo Livongo empowers people with chronic conditions to live better and healthier lives, beginning with diabet...

Valens Research
  • Valens Research

Valens Equity Insights and Inflections - 2020 09 08

BHC currently trades well below corporate averages relative to Uniform earnings, with a 9.1x Uniform P/E. At these levels, the market is pricing in expectations for Uniform ROA to fall from 45% in 2019 to 20% in 2024, accompanied by 2% Uniform asset growth going forward. However, analysts have bullish expectations, projecting Uniform ROA to expand to 51% by 2021, accompanied by 3% Uniform asset shrinkage. Furthermore, management is confident about the eye health spinoff, script recovery, and Pro...

 PRESS RELEASE

Livongo to Present at Upcoming Investor Conferences

Livongo to Present at Upcoming Investor Conferences MOUNTAIN VIEW, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Livongo Health, Inc., (Nasdaq: LVGO), the leading Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, today announced that executives from the Company, together with executives from Teladoc Health, will be presenting at the following upcoming investor conferences and discussing their pending merger: Wells Fargo Securities Healthcare Conference on Thursday, September 10 at 8:00 a.m. Eastern TimeMorgan Stanley 18th Annual Glo...

Valens Research
  • Valens Research

LVGO - Embedded Expectations Analysis - 2020 09 02

Livongo Health, Inc. (LVGO:USA) currently trades above historical averages relative to UAFRS-based (Uniform) earnings, with a 166.3x Uniform P/E. At these levels, the market has bullish expectations for the firm, but management may be concerned about running at a net loss, Teladoc merger benefits, and the usefulness of their diabetes studies Specifically, management may lack confidence in their ability to generate a net profit, sustain Adjusted EBITDA growth, and continue generating contract wi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch